Esperion Therapeutics filings document the regulatory record of a commercial-stage biopharmaceutical company focused on LDL-C lowering, cardiovascular-risk therapies, and related cardiometabolic programs. Its Form 8-K reports cover operating and financial results, clinical or regulatory disclosures, material agreements, capital-structure matters, and material-event updates tied to its commercial portfolio and development activities.
Esperion's SEC record also includes proxy disclosures on shareholder voting, board governance, executive compensation, equity awards, and pay-versus-performance information. Recent filings describe common stock registered on Nasdaq under ESPR, term-loan and credit-agreement amendments, acquisition-related financing, commercial leadership appointments, and other governance and compensation arrangements.
Two Seas Capital LP, Two Seas Capital GP LLC and Sina Toussi report beneficial ownership of 9,954,975 shares of Esperion Therapeutics common stock, representing 5.0% of the class based on 198,199,462 shares outstanding. The shares are held by Two Seas Global (Master) Fund LP, for which Two Seas Capital acts as investment adviser and has sole voting and dispositive power; TSC GP and Mr. Toussi are identified through their general partner and managing member roles.
The filing states the position is held in the ordinary course of business and not to change or influence control of the issuer. The disclosure quantifies position size and control over voting and disposition rights without indicating an intent to seek corporate control.
Esperion Therapeutics has registered an additional 6,250,000 shares of its common stock for issuance under the company’s 2022 Stock Option and Incentive Plan, as amended, following stockholder approval of the plan amendment on May 29, 2025. The Registration Statement on Form S-8 incorporates prior Form S-8 registration statements for the same class of securities.
This filing enables the company to grant additional equity awards under its incentive plan; it is a routine corporate step to implement the expanded reserve and does not itself change outstanding shares until awards are issued and exercised.
Esperion Therapeutics reported continued U.S. commercial momentum for its oral, non‑statin LDL‑C medicines as product sales rose to $40.3 million in Q2 2025 and $75.2 million for the six months ended June 30, 2025, up from $28.3 million and $53.1 million in the comparable 2024 periods, indicating stronger prescriptions and channel activity.
Collaboration revenue was approximately $42.1 million in Q2 2025 and $72.2 million year‑to‑date, down from $158.5 million for the prior six‑month period largely because prior‑year results included larger milestone recognition. Cash and cash equivalents declined to $86.1 million at June 30, 2025 from $144.8 million at December 31, 2024. Total assets were $347.1 million and total liabilities increased to $780.6 million, resulting in a stockholders' deficit of $(433.5) million.
The company recognized notable finance and capital transactions: proceeds from a $304.7 million sale of future DSE royalties are recorded as a royalty sale liability of approximately $295.9 million (net of issuance costs), and it maintains long‑term debt from a $150.0 million term loan with a carrying amount of $146.5 million. Interest expense increased year‑over‑year and contributed to a consolidated net loss of $53.18 million for the six months ended June 30, 2025. Esperion settled patent disputes with three ANDA filers who agreed not to market a generic version of NEXLETOL in the U.S. before April 19, 2040, while litigation against remaining ANDA filers continues.
Esperion Therapeutics, Inc. notified the SEC that it cannot timely file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 because it has not completed its quarter-end financial close. Management identified errors in an earnings release previously furnished and subsequently amended; the amended release contains preliminary, unaudited financial data based on management estimates that remain subject to completion of closing procedures. The Company requires additional time to finalize its condensed financial statements.
Esperion states it expects to file the Form 10-Q as soon as practicable and no later than the five-calendar-day extension permitted by Rule 12b-25. The filing notes that all other periodic reports for the last 12 months have been filed and that the Company does not anticipate a significant change in results versus the comparable prior-year period. Contact: Sheldon L. Koenig, President and CEO.
Esperion Therapeutics filed an Amendment No. 1 to its Form 8-K to correct its August 5, 2025 earnings release. The amendment corrects the Balance Sheet Data for the period ended June 30, 2025 and the Statement of Operations for the three and six months ended June 30, 2025, specifically net income (loss), net income (loss) per share, and income from operations for the three-month period. A corrected earnings release is furnished as Exhibit 99.1 dated August 11, 2025. Management states these figures are preliminary, unaudited, and subject to completion of the quarter-end close and may change; all other disclosures remain unchanged.
Esperion Therapeutics (ESPR) – Form 4 filing: On 07/01/2025 director John Craig Thompson received an option grant for 40,000 shares of common stock at an exercise price of $1.00 per share. The options vest in three equal annual installments beginning 07/01/2026 and expire on 07/01/2035. No common shares were bought or sold; the transaction is classified as an "A" (grant) and the beneficial ownership is reported as direct. Following the grant, Thompson beneficially owns 40,000 derivative securities (options) and no change was reported in non-derivative share ownership.
Esperion Therapeutics, Inc. (NASDAQ: ESPR) has appointed Craig Thompson, MBA, a veteran biotechnology executive, to its Board of Directors effective July 1, 2025. Thompson will serve as an independent Class II director with a term running through the 2027 annual meeting. He will immediately join the Compliance, Nominating & Corporate Governance, and Commercial Committees.
Thompson brings more than two decades of commercial and C-suite experience to Esperion. He is currently CEO of Cerevance, LLC and holds board seats at NervGen Pharma. His prior leadership roles include CEO positions at Neurana, Anthera and senior commercial posts at Tetraphase, Trius, Pfizer and Merck, where he helped launch high-profile cardiovascular products such as Zocor and oversaw the global commercial development of torcetrapib/atorvastatin.
Under Esperion’s non-employee director compensation plan, Thompson will receive standard cash retainers and equity awards. The company has executed a customary indemnification agreement with him. No related-party transactions were disclosed.
A press release announcing the appointment was furnished as Exhibit 99.1 under Item 7.01; the disclosure is deemed “furnished” and not “filed” under the Exchange Act.